Cargando…

How to remove those bloody collections: Nonsurgical treatment options for chronic subdural hematoma

Chronic subdural hematoma (CSDH) is one of the most prevalent neurosurgical disorders. Patients with CSDH commonly present with altered mental status, focal neurological deficit, and/or headache. The first-line treatment for CSDH is surgical evacuation. Although the surgical procedures for CSDH have...

Descripción completa

Detalles Bibliográficos
Autores principales: Yun, Ho Jun, Ding, Yuchuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7821810/
https://www.ncbi.nlm.nih.gov/pubmed/33506148
http://dx.doi.org/10.4103/bc.bc_73_20
_version_ 1783639502860845056
author Yun, Ho Jun
Ding, Yuchuan
author_facet Yun, Ho Jun
Ding, Yuchuan
author_sort Yun, Ho Jun
collection PubMed
description Chronic subdural hematoma (CSDH) is one of the most prevalent neurosurgical disorders. Patients with CSDH commonly present with altered mental status, focal neurological deficit, and/or headache. The first-line treatment for CSDH is surgical evacuation. Although the surgical procedures for CSDH have been considered relatively “straightforward,” they are not without any risk. The elderly are especially prone to show poor surgical outcomes. To make matters worse, many elderly patients are on anticoagulants and antiplatelet agents, increasing the risk of re-bleeding before and after surgery. These complications have led clinicians to search for nonsurgical alternatives. Dexamethasone should be used with caution for selected patients given its side effects. Tranexamic acid may be utilized as an adjunct therapy to surgery, but more randomized clinical trials are needed to evaluate its definitive efficacy. Interesting results of middle meningeal artery embolization (MMAE) have been reported from case studies. However, the risks associated with MMAE, including intracerebral hemorrhage, stroke, and vasospasm, have not been properly studied yet. The clinical benefits of atorvastatin and angiotensin-converting enzyme inhibitors are uncertain for CSDH. In conclusion, surgical intervention continues to be the first-line treatment while nonsurgical treatment options may be considered an adjunct therapy especially for recurrent hematoma or to reduce the volume of a hematoma.
format Online
Article
Text
id pubmed-7821810
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-78218102021-01-26 How to remove those bloody collections: Nonsurgical treatment options for chronic subdural hematoma Yun, Ho Jun Ding, Yuchuan Brain Circ Review Article Chronic subdural hematoma (CSDH) is one of the most prevalent neurosurgical disorders. Patients with CSDH commonly present with altered mental status, focal neurological deficit, and/or headache. The first-line treatment for CSDH is surgical evacuation. Although the surgical procedures for CSDH have been considered relatively “straightforward,” they are not without any risk. The elderly are especially prone to show poor surgical outcomes. To make matters worse, many elderly patients are on anticoagulants and antiplatelet agents, increasing the risk of re-bleeding before and after surgery. These complications have led clinicians to search for nonsurgical alternatives. Dexamethasone should be used with caution for selected patients given its side effects. Tranexamic acid may be utilized as an adjunct therapy to surgery, but more randomized clinical trials are needed to evaluate its definitive efficacy. Interesting results of middle meningeal artery embolization (MMAE) have been reported from case studies. However, the risks associated with MMAE, including intracerebral hemorrhage, stroke, and vasospasm, have not been properly studied yet. The clinical benefits of atorvastatin and angiotensin-converting enzyme inhibitors are uncertain for CSDH. In conclusion, surgical intervention continues to be the first-line treatment while nonsurgical treatment options may be considered an adjunct therapy especially for recurrent hematoma or to reduce the volume of a hematoma. Wolters Kluwer - Medknow 2020-12-29 /pmc/articles/PMC7821810/ /pubmed/33506148 http://dx.doi.org/10.4103/bc.bc_73_20 Text en Copyright: © 2020 Brain Circulation http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Review Article
Yun, Ho Jun
Ding, Yuchuan
How to remove those bloody collections: Nonsurgical treatment options for chronic subdural hematoma
title How to remove those bloody collections: Nonsurgical treatment options for chronic subdural hematoma
title_full How to remove those bloody collections: Nonsurgical treatment options for chronic subdural hematoma
title_fullStr How to remove those bloody collections: Nonsurgical treatment options for chronic subdural hematoma
title_full_unstemmed How to remove those bloody collections: Nonsurgical treatment options for chronic subdural hematoma
title_short How to remove those bloody collections: Nonsurgical treatment options for chronic subdural hematoma
title_sort how to remove those bloody collections: nonsurgical treatment options for chronic subdural hematoma
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7821810/
https://www.ncbi.nlm.nih.gov/pubmed/33506148
http://dx.doi.org/10.4103/bc.bc_73_20
work_keys_str_mv AT yunhojun howtoremovethosebloodycollectionsnonsurgicaltreatmentoptionsforchronicsubduralhematoma
AT dingyuchuan howtoremovethosebloodycollectionsnonsurgicaltreatmentoptionsforchronicsubduralhematoma